Silo Pharma Inc. (Silo Pharma (SILO)) announced Tuesday that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices Inc.'s (AMD (AMD)) AI Developer Program. The program gives QwikAgents access to cloud computing credits, AI development tools, training resources, and a global developer network — all aimed at accelerating the platform's growth.
Silo Pharma shares initially traded higher on the news before pulling back and turning negative. At the time of publication, shares were down 4.36% at $5.05.
The company said participation in the program is expected to support the continued development, testing, optimization, and benchmarking of QwikAgents' artificial intelligence workloads as it broadens the platform's consumer and enterprise capabilities.
Platform Targets Individuals, Developers And Businesses
QwikAgents is building a next-generation AI agent platform designed to provide dedicated, persistent AI agents for individuals, developers, small businesses, and enterprises. According to the company, users can deploy blank AI agents and, in the future, purpose-built agents for tasks including research, content generation, scheduling, coding, browser automation, and workflow automation.
Starter plans are expected to begin at $14 per month, with infrastructure options that scale for more demanding workloads. The platform is also being designed to combine persistent memory, dedicated agent infrastructure, smart model routing, and encrypted backups with a simplified deployment process. Silo Pharma said these features are intended to provide configurable AI agents across personal, developer, and business workflows.
AMD Program Expected To Support Platform Scaling
Silo Pharma expects access to AMD's developer resources to help improve platform performance, increase agent reliability, and support the scalable deployment of autonomous AI agents capable of reasoning, executing tasks, and completing workflows with minimal human intervention.
Beyond its AI initiative, Silo Pharma remains a developmental-stage biopharmaceutical company focused on therapies for underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Its pipeline includes SPC-15 for post-traumatic stress disorder, SP-26 for fibromyalgia and chronic pain, and a preclinical program targeting Alzheimer's disease.
